Key Highlights
- Mirum Pharmaceuticals (NASDAQ:MIRM) rose about 5.2% to USD 85.58 in the October 9, 2026 session, with no company announcement found, while its September 28 AZURE-1 Phase 3 win remains the main backdrop.
- GRAIL (NASDAQ:GRAL) gained about 5% to USD 139.30 with no announcement found, and its September 23 FDA panel vote of 7 in favor, 2 against and 1 abstaining on the Galleri test is the central pending event.
- Reportedly, JPMorgan started coverage of C4 Therapeutics (NASDAQ:CCCC) on October 9 with an Overweight rating and a USD 10 target, the only candidate reason for its 5.65% gain, and it is unconfirmed.
- Immunic (NASDAQ:IMUX) rose 5.56% on reported multiple sclerosis data presentations. A reported BofA target change accompanied a 5.65% gain for 10x Genomics (NASDAQ:TXG), though neither link to the move is proven.
Mirum Pharmaceuticals (NASDAQ:MIRM): Quiet Gain After the AZURE-1 Win
Mirum Pharmaceuticals (NASDAQ:MIRM) rose about 5.2% to USD 85.58 in the October 9, 2026 session, with no catalyst identified, and no company announcement was found for October 8 or 9. Published market data showed a close near USD 81.35 on October 8, which fits the gain. The backdrop is the September 28, 2026 Phase 3 AZURE-1 result, where brelovitug met its primary endpoint in chronic hepatitis delta: 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks reached the Week 24 endpoint, versus 0% for delayed treatment. Reportedly, several analysts raised price targets after the readout, but nothing ties those notes to October 9. The shares have a wide 52-week range of roughly USD 63.23 to USD 130.00, per published market data, which shows how volatile they have been. The second pivotal study, AZURE-4, is expected in the fourth quarter of 2026, and regulators could ask for more data. A BLA filing is planned for the first half of 2027, if regulators agree.
GRAIL (NASDAQ:GRAL): Waiting on the FDA After a Narrow Panel Vote
GRAIL (NASDAQ:GRAL) rose about 5% to USD 139.30 in the October 9, 2026 session, and no company announcement was found for October 8 or 9. Published market data showed a close near USD 132.61 on October 8. On September 23, 2026 an FDA advisory panel voted 7 to 2 with 1 abstention that Galleri benefits outweigh risks for adults aged 50 and older, backed safety unanimously and split 6 to 4 on effectiveness. The premarket approval application was submitted on January 29, 2026, and the FDA is not bound by the panel. Risks include reimbursement, since published reports say Galleri sells for about USD 700 out of pocket and most insurers do not cover it, a UK trial that did not significantly cut late-stage diagnoses overall, and trailing Revenue of about USD 165 million against a net loss near USD 392 million. GRAIL (NASDAQ:GRAL) has also rallied sharply into the decision.
C4 Therapeutics (NASDAQ:CCCC): An Analyst Initiation and a Long Runway
C4 Therapeutics (NASDAQ:CCCC) rose about 5.7% to USD 3.01 in the October 9, 2026 session, with no catalyst identified. Reportedly, JPMorgan initiated coverage that day with an Overweight rating and a USD 10 price target. No company announcement was found, and the initiation rests on a single report, so it is a candidate reason rather than a proven one. The lead program is cemsidomide for multiple myeloma, which showed a 53% overall response rate at the 100 microgram dose in a June 2026 presentation. Cash was USD 300.4 million on June 30, 2026, which the company expects to fund operations through the end of 2028. Risks include at-the-market share sales, which add dilution, early trial data that can disappoint, and competition from approved bispecifics and cell therapies. Company-sponsored pivotal readouts are not due until 2027, so C4 Therapeutics (NASDAQ:CCCC) trades on opinion for now. The 52-week range of roughly USD 1.69 to USD 5.17 also shows how wide the swings have been.
Immunic (NASDAQ:IMUX): Reported Data Ahead of Phase 3 Readouts
Immunic (NASDAQ:IMUX) rose about 5.6% to USD 7.98 in the October 9, 2026 session, with market data labelling the move as news. Published market data shows the company announced clinical, biomarker and preclinical data for vidofludimus calcium at MSToronto2026 around October 7, but the company release was not located, so the date and the link to October 9 are unverified. The decisive event is topline data from the Phase 3 ENSURE-1 and ENSURE-2 trials in relapsing multiple sclerosis, expected by the end of 2026. Cash was USD 155.1 million on June 30, 2026, which the company says funds operations into late 2027, and the second quarter net loss was about USD 34.1 million. Binary trial risk is large, and that runway is shorter than the time needed to launch a drug, so financing is likely and dilution is a real risk. Immunic (NASDAQ:IMUX) is a pre-revenue company, and the 52-week range of roughly USD 5.06 to USD 17.43 shows how far the shares have moved.
10x Genomics (NASDAQ:TXG): Target Raises Chase a Volatile Rally
10x Genomics (NASDAQ:TXG) rose about 5.7% to USD 81.85 in the October 9, 2026 session, with market data labelling the move as news. Reportedly, BofA raised its price target to USD 80 from USD 50 on October 9 while keeping a Neutral rating, but no company filing was found for the day. The same reports describe a 13.4% drop around October 7, so the shares swing hard. Second quarter 2026 revenue was USD 151 million, instruments fell 47% and consumables rose 7%, and 2026 revenue guidance was raised to USD 610 million to USD 630 million. The Atera spatial platform is the growth story, with about 40 systems expected to ship in 2026, mostly in the fourth quarter. Risks include production delays, uneven academic funding and an average analyst target near USD 67, below the quoted price. 10x Genomics (NASDAQ:TXG) next reports around November 5, 2026, per an estimate. Figures are session snapshots.
Where Things Stand
All five names rose in the October 9, 2026 session, but none had a confirmed company announcement that day, so the catalysts are mostly unverified. Mirum Pharmaceuticals (NASDAQ:MIRM) trades on earlier trial news. GRAIL (NASDAQ:GRAL) trades on a pending FDA decision. Reported analyst notes touch C4 Therapeutics (NASDAQ:CCCC). The same holds for 10x Genomics (NASDAQ:TXG). Immunic (NASDAQ:IMUX) awaits Phase 3 data by the end of 2026. Gains of 5% to 6% in one session can reverse quickly.






Please wait processing your request...